<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">psychiatry</journal-id><journal-title-group><journal-title xml:lang="ru">ПСИХИАТРИЯ</journal-title><trans-title-group xml:lang="en"><trans-title>Psychiatry (Moscow) (Psikhiatriya)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1683-8319</issn><issn pub-type="epub">2618-6667</issn><publisher><publisher-name>FSBSI “The Mental Health Research Centre”;   LLC «Publisher «MIA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30629/2618-6667-2020-18-4-93-113</article-id><article-id custom-type="elpub" pub-id-type="custom">psychiatry-552</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НАУЧНЫЕ ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SCIENTIFIC REVIEWS</subject></subj-group></article-categories><title-group><article-title>Деменции позднего возраста: факторы, ассоциированные со скоростью прогрессирования деменции. Часть 2</article-title><trans-title-group xml:lang="en"><trans-title>Old Age Dementias: Factors Associated with Dementia Progression Rate. Part 2</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0184-016X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Михайлова</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Mikhaylova</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михайлова Наталия Михайловна, доктор медицинских наук</p><p>Москва</p></bio><bio xml:lang="en"><p> </p><p>Moscow</p></bio><email xlink:type="simple">MikhaylovaNM@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научный центр психического здоровья»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FGBSI “Mental Health Research Centre”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2020</year></pub-date><volume>18</volume><issue>4</issue><fpage>93</fpage><lpage>113</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Михайлова Н.М., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Михайлова Н.М.</copyright-holder><copyright-holder xml:lang="en">Mikhaylova N.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.journalpsychiatry.com/jour/article/view/552">https://www.journalpsychiatry.com/jour/article/view/552</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование: неуклонное прогрессирование деменции характеризуется разной скоростью, что обусловило клиническое разграничение деменций с быстрым и медленным нарастанием тяжести когнитивного снижения. Поиск клинических факторов, гипотетически ответственных за различия в скорости прогрессирования деменции, является одним из аспектов исследований проблемы деменций позднего возраста.</p></sec><sec><title>Цель</title><p>Цель: обобщить результаты изучения влияния отдельных клинических факторов на различия в темпе прогрессирования деменций позднего возраста.</p></sec><sec><title>Материал и метод</title><p>Материал и метод: по ключевым словам «поздний возраст», «деменция», «скорость прогрессирования», «возраст начала», «некогнитивные расстройства», «нозомодифицирующая терапия» отобраны и проанализированы статьи в базах MEDLINE/PubMed с 1990 по 2020 г., а также релевантные статьи в списках литературы анализированных работ.</p></sec><sec><title>Заключение</title><p>Заключение: различные параметры заболевания исследованы в качестве ассоциированных с паттерном прогрессирования деменции. В отношении части из них результаты достигали согласованности в признании связи со скоростью прогрессирования деменции, в отношении других такие свидетельства неоднозначные. Большие расхождения имеются во взглядах на гендерные различия, в то время как ранний возраст начала заболевания, исходно бóльшая выраженность когнитивного снижения, массивность нейропсихиатрических расстройств согласованно признаются ассоциированными с быстрым прогрессированием деменции. Исследователей объединяет устойчивое представление о нелинейном характере прогрессирования деменции на этапах мягкой, умеренной и тяжелой деменции.</p><p>Результаты изучения коморбидности в основном сходны в отношении признания влияния СФР, прежде всего артериальной гипертензии, на скорость прогрессирования деменции. Доказательство эффективности нозомодифицирующей терапии, замедляющей прогрессирование деменции, единодушно считается актуальной задачей, решению которой способствует разработка новых концепций патогенеза деменций и поиск новых мишеней терапии. Результаты изученного направления исследований подтверждают гипотезу о том, что прогрессирование деменции происходит по различным патогенетическим механизмам, которые определяют скорость нарастания деменции. Ведение больных деменцией в практике предполагает учет различных факторов, влияющих на скорость прогрессирования деменции, для планирования объема и характера лечебной помощи.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background: steady progression of dementia is characterized with various rates, which specified clinical differentiation of dementias with rapid and slow increase of cognitive decline severity. The search for clinical factors, hypothetically responsible for differences in late age dementia progression rate, is one of the aspects of investigation of late age dementias.</p><p>The objective was to generalize the results of the study of separate clinical factors effect on the differences in the late age dementia progression rate.</p></sec><sec><title>Material and methods</title><p>Material and methods: papers in MEDLINE/PubMed bases from 1990 to 2020 were selected and analyzed according to the key words: “late age”, “dementia”, “progression rate”, “age of onset”, “non-cognitive disorders”, “nosomodifying therapy”, as well as relevant papers in the literature of the analyzed works.</p></sec><sec><title>Conclusion</title><p>Conclusion: various parameters of the disease were studied as associated with dementia progression pattern. As regards part of them the results achieved compliance in recognition of association with dementia progression rate. As for the others this evidence is ambiguous. There are large discrepancies in attitudes to gender differences, while early age of disease onset, initially great intensity of neuropsychiatric disorders are concordantly admitted as associated with dementia rapid progression. The researchers are united with steady idea of nonlinear character of dementia progression at the stages of mild, moderate and severe dementia.</p><p>The results of study of comorbidity are basically similar with regard to recognition of SFD influence, first of all, of arterial hypertension on dementia progression rate. The evidence of the efficacy of nosomodifying therapy, decelerating dementia progression, is unanimously considered an urgent problem. The development of new dementia pathogenesis concepts and the search for new therapy targets, are conducive to the solution of this problem. The results of the investigated direction of studies confirm the hypothesis of the fact that dementia progression occurs according to various pathogenetic mechanisms, which determine the dementia increasing rate. The management of patients with dementia in practice presupposes taking into account of various factors, influencing dementia progression rate, for planning of the volume and character of medical care.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>поздний возраст</kwd><kwd>деменция</kwd><kwd>скорость прогрессирования</kwd><kwd>возраст начала</kwd><kwd>некогнитивные расстройства</kwd><kwd>нозомодифицирующая терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>old age</kwd><kwd>dementia</kwd><kwd>progression rate</kwd><kwd>age of onset</kwd><kwd>non-cognitive disorders</kwd><kwd>nosomodifying therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">McCarten JR, Hemmy LS, Rottunda SJ, Kuskowski MA. Patient Age Influence Recognition of Alzheimer’s Disease. J. Gerontol. 2008;63(6):625–628. DOI: 10.1093/gerona/63.6.625</mixed-citation><mixed-citation xml:lang="en">McCarten JR, Hemmy LS, Rottunda SJ, Kuskowski MA. Patient Age Influence Recognition of Alzheimer’s Disease. J. Gerontol. 2008;63(6):625–628. DOI: 10.1093/gerona/63.6.625</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL. A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am. J. Psychiatry. 1994;151(3):390–396. DOI: 10.1176/ajp.151.3.390</mixed-citation><mixed-citation xml:lang="en">Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL. A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am. J. Psychiatry. 1994;151(3):390–396. DOI: 10.1176/ajp.151.3.390</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Handels RL, Xu W, Rizzuto D, Caracciolo B, Wang R, Winblad B, Verhey FR, Severens JL, Fratiglioni L, Joore MA, Wimo A. Natural progression model of cognition and physical functioning among people with mild cognitive impairment and Alzheimer’s disease. J. Alzheimers Dis. 2013;37(2):357–365. DOI: 10.3233/JADDOI130296</mixed-citation><mixed-citation xml:lang="en">Handels RL, Xu W, Rizzuto D, Caracciolo B, Wang R, Winblad B, Verhey FR, Severens JL, Fratiglioni L, Joore MA, Wimo A. Natural progression model of cognition and physical functioning among people with mild cognitive impairment and Alzheimer’s disease. J. Alzheimers Dis. 2013;37(2):357–365. DOI: 10.3233/JADDOI130296</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Schulz R, Zdaniuk B, Belle SH, Czaja SJ, Michael Arrighi H, Zbrozek AS. Baseline differences and trajectories of change for deceased, placed, and community residing Alzheimer disease patients. Alzheimer Dis. Assoc. Disord. 2010;24:143–150. DOI: 10.1097/WAD.0b013e3181b795b7</mixed-citation><mixed-citation xml:lang="en">Schulz R, Zdaniuk B, Belle SH, Czaja SJ, Michael Arrighi H, Zbrozek AS. Baseline differences and trajectories of change for deceased, placed, and community residing Alzheimer disease patients. Alzheimer Dis. Assoc. Disord. 2010;24:143–150. DOI: 10.1097/WAD.0b013e3181b795b7</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Yoon B, Shim YS, Park HK, Park SA, Choi SH, Yang DW. Predictive factors for disease progression in patients with early-onset Alzheimer’s disease. J. Alzheimers Dis. 2016;49(1):85–91. DOI: 10.3233/JAD-15046</mixed-citation><mixed-citation xml:lang="en">Yoon B, Shim YS, Park HK, Park SA, Choi SH, Yang DW. Predictive factors for disease progression in patients with early-onset Alzheimer’s disease. J. Alzheimers Dis. 2016;49(1):85–91. DOI: 10.3233/JAD-15046</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tchalla AE, Clément JP, Saulnier I, Beaumatin B, Lachal F, Gayot C, Bosetti A, Desormais I, Perrochon A, Preux PM, Couratier P, Dantoine T. Predictors of Rapid Cognitive Decline in Patients with Mild-to-Moderate Alzheimer Disease: A Prospective Cohort Study with 12-Month Follow-Up Performed in Memory Clinics. Dement. Geriatr. Cogn. Disord. 2018;45(1–2):56–65. DOI: 10.1159/000487938</mixed-citation><mixed-citation xml:lang="en">Tchalla AE, Clément JP, Saulnier I, Beaumatin B, Lachal F, Gayot C, Bosetti A, Desormais I, Perrochon A, Preux PM, Couratier P, Dantoine T. Predictors of Rapid Cognitive Decline in Patients with Mild-to-Moderate Alzheimer Disease: A Prospective Cohort Study with 12-Month Follow-Up Performed in Memory Clinics. Dement. Geriatr. Cogn. Disord. 2018;45(1–2):56–65. DOI: 10.1159/000487938</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Herrmann N, Harimoto T, Balshaw R, Lanctôt KL; Canadian Outcomes Study in Dementia (COSID) Investigators. Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID). Can. J. Psychiatry. 2015;60(4):189–99. DOI: 10.1177/070674371506000406</mixed-citation><mixed-citation xml:lang="en">Herrmann N, Harimoto T, Balshaw R, Lanctôt KL; Canadian Outcomes Study in Dementia (COSID) Investigators. Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID). Can. J. Psychiatry. 2015;60(4):189–99. DOI: 10.1177/070674371506000406</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bhargava D, Weiner MF, Hynan LS, Diaz-Arrastia R, Lipton AM. Vascular disease and risk factors, rate of progression, and survival in Alzheimer’s disease. J. Geriatr. Psychiatry Neurol. 2006;19(2):78–82. DOI: 10.1177/0891988706286505</mixed-citation><mixed-citation xml:lang="en">Bhargava D, Weiner MF, Hynan LS, Diaz-Arrastia R, Lipton AM. Vascular disease and risk factors, rate of progression, and survival in Alzheimer’s disease. J. Geriatr. Psychiatry Neurol. 2006;19(2):78–82. DOI: 10.1177/0891988706286505</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Canevelli M, Kelaiditi E, Del Campo N, Bruno G, Vellas B, Cesari M; ICTUSDSA group. Predicting the Rate of Cognitive Decline in Alzheimer Disease: Data From the ICTUS Study. Alzheimer Dis. Assoc. Disord. 2016;30(3):237–42. DOI: 10.1097/WAD.0000000000000124</mixed-citation><mixed-citation xml:lang="en">Canevelli M, Kelaiditi E, Del Campo N, Bruno G, Vellas B, Cesari M; ICTUSDSA group. Predicting the Rate of Cognitive Decline in Alzheimer Disease: Data From the ICTUS Study. Alzheimer Dis. Assoc. Disord. 2016;30(3):237–42. DOI: 10.1097/WAD.0000000000000124</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Jia J, Gauthier S, Pallotta S, Ji Y, Wei W, Xiao S, Peng D, Guo Q, Wu L, Chen S, Kuang W, Zhang J, Wei C, Tang Y. Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer’s disease. Alzheimer’s Dement. 2017;13(5):592–597. DOI: 10.1016/j.jalz.2017.01.0070</mixed-citation><mixed-citation xml:lang="en">Jia J, Gauthier S, Pallotta S, Ji Y, Wei W, Xiao S, Peng D, Guo Q, Wu L, Chen S, Kuang W, Zhang J, Wei C, Tang Y. Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer’s disease. Alzheimer’s Dement. 2017;13(5):592–597. DOI: 10.1016/j.jalz.2017.01.0070</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sinforiani E1, Bernini S, Picascia M. Disease progression in relation to age at onset in a population with Alzheimer’s Dementia. Aging. Clin. Exp. Res. 2018;31(5):723–725. DOI: 10.1007/s40520-018-1027-5</mixed-citation><mixed-citation xml:lang="en">Sinforiani E1, Bernini S, Picascia M. Disease progression in relation to age at onset in a population with Alzheimer’s Dementia. Aging. Clin. Exp. Res. 2018;31(5):723–725. DOI: 10.1007/s40520-018-1027-5</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Doody RS, Massman P, Dunn JK. A Method for Estimating Progression Rates in Alzheimer’s Disease. Arch. Neurol. 2001;58:449–453. DOI: 10.1001/archneur.58.3.449</mixed-citation><mixed-citation xml:lang="en">Doody RS, Massman P, Dunn JK. A Method for Estimating Progression Rates in Alzheimer’s Disease. Arch. Neurol. 2001;58:449–453. DOI: 10.1001/archneur.58.3.449</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bruandet A, Richard F, Bombois S, Maurage CA, Masse I, Amouyel P, Pasquier F. Cognitive decline and survival in Alzheimer’s disease according to education level. Dement Geriatr. Cogn. Disord. 2008;25(1):74–80. DOI: 10.1159/000111693</mixed-citation><mixed-citation xml:lang="en">Bruandet A, Richard F, Bombois S, Maurage CA, Masse I, Amouyel P, Pasquier F. Cognitive decline and survival in Alzheimer’s disease according to education level. Dement Geriatr. Cogn. Disord. 2008;25(1):74–80. DOI: 10.1159/000111693</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Chaves ML, Camozzato AL, Köhler C, Kaye J. Predictors of the Progression of Dementia Severity in Brazilian Patients with Alzheimer’s Disease and Vascular Dementia. Int. J. Alzheimer’s Disease. 2010;2010:673581. Published 2010 Mar 14. DOI: 10.4061/2010/673581</mixed-citation><mixed-citation xml:lang="en">Chaves ML, Camozzato AL, Köhler C, Kaye J. Predictors of the Progression of Dementia Severity in Brazilian Patients with Alzheimer’s Disease and Vascular Dementia. Int. J. Alzheimer’s Disease. 2010;2010:673581. Published 2010 Mar 14. DOI: 10.4061/2010/673581</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Thalhauser CJ, Komarova NL Alzheimer’s disease: rapid and slow progression. J. R. Soc. Interface. 2012;9(66):119–126. DOI: 10.1098/rsif.2011.0134</mixed-citation><mixed-citation xml:lang="en">Thalhauser CJ, Komarova NL Alzheimer’s disease: rapid and slow progression. J. R. Soc. Interface. 2012;9(66):119–126. DOI: 10.1098/rsif.2011.0134</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Valenzuela M, Brayne C, Sachdev P, Wilcock G, Matthews F; Medical Research Council Cognitive Function and Ageing Study. Cognitive Lifestyle and Long-Term Risk of Dementia and Survival After Diagnosis in a Multicenter Population-based Cohort. Am. J. Epidemiol. 2011;173(9):1004–1012.DOI: 10.1093/aje/kwq476</mixed-citation><mixed-citation xml:lang="en">Valenzuela M, Brayne C, Sachdev P, Wilcock G, Matthews F; Medical Research Council Cognitive Function and Ageing Study. Cognitive Lifestyle and Long-Term Risk of Dementia and Survival After Diagnosis in a Multicenter Population-based Cohort. Am. J. Epidemiol. 2011;173(9):1004–1012.DOI: 10.1093/aje/kwq476</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Day GS, Musiek ES, Morris JC. Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. Alzheimer Dis. Assoc. Disord. 2018;32(4):291–297. DOI: 10.1097/WAD.0000000000000276</mixed-citation><mixed-citation xml:lang="en">Day GS, Musiek ES, Morris JC. Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. Alzheimer Dis. Assoc. Disord. 2018;32(4):291–297. DOI: 10.1097/WAD.0000000000000276</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Castrillo Sanz A, Andrés Calvo M, Repiso Gento I, Izquierdo Delgado E, Gutierrez Ríos R, Rodríguez Herrero R, Rodríguez Sanz F, Tola-Arribas MA. Anosognosia in Alzheimer disease: Prevalence, associated factors, and influence on disease progression. Neurologia. 2016;31(5):296–304. DOI: 10.1016/j.nrl.2015.03.006</mixed-citation><mixed-citation xml:lang="en">Castrillo Sanz A, Andrés Calvo M, Repiso Gento I, Izquierdo Delgado E, Gutierrez Ríos R, Rodríguez Herrero R, Rodríguez Sanz F, Tola-Arribas MA. Anosognosia in Alzheimer disease: Prevalence, associated factors, and influence on disease progression. Neurologia. 2016;31(5):296–304. DOI: 10.1016/j.nrl.2015.03.006</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Groot C, van Loenhoud AC, Barkhof F, van Berckel BNM, Koene T, Teunissen CC, Scheltens P, van der Flier WM, Ossenkoppele R. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. 2018;90(2):149–156. DOI: 10.1212/WNL.0000000000004802</mixed-citation><mixed-citation xml:lang="en">Groot C, van Loenhoud AC, Barkhof F, van Berckel BNM, Koene T, Teunissen CC, Scheltens P, van der Flier WM, Ossenkoppele R. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. 2018;90(2):149–156. DOI: 10.1212/WNL.0000000000004802</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Seidl JN, Massman PJ. Rapidly Versus Slowly Progressing Patients With Alzheimer’s Disease: Differences in Baseline Cognition. Am. J. Alzheimers Dis. Other Demen. 2016;31(4):318–25. DOI: 10.1177/1533317515617720</mixed-citation><mixed-citation xml:lang="en">Seidl JN, Massman PJ. Rapidly Versus Slowly Progressing Patients With Alzheimer’s Disease: Differences in Baseline Cognition. Am. J. Alzheimers Dis. Other Demen. 2016;31(4):318–25. DOI: 10.1177/1533317515617720</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Dharmasaroja PA, Lolekha P, Kulkantrakorn K, Charernboon T, Watcharakorn A, Piyabhan P. Natural course and predictors of severe disability and death in Thai patients with dementia. J. Clin. Neurosci. 2017;46:37–40. DOI: 10.1016/j.jocn.2017.08.040</mixed-citation><mixed-citation xml:lang="en">Dharmasaroja PA, Lolekha P, Kulkantrakorn K, Charernboon T, Watcharakorn A, Piyabhan P. Natural course and predictors of severe disability and death in Thai patients with dementia. J. Clin. Neurosci. 2017;46:37–40. DOI: 10.1016/j.jocn.2017.08.040</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Barocco F, Spallazzi M, Concari L, Gardini S, Pelosi A, Caffarra P. The Progression of Alzheimer’s Disease: Are Fast Decliners Really Fast? A Four-Year Follow-Up. J. Alzheimers Dis. 2017;57(3):775–786.DOI: 10.3233/JAD-161264</mixed-citation><mixed-citation xml:lang="en">Barocco F, Spallazzi M, Concari L, Gardini S, Pelosi A, Caffarra P. The Progression of Alzheimer’s Disease: Are Fast Decliners Really Fast? A Four-Year Follow-Up. J. Alzheimers Dis. 2017;57(3):775–786.DOI: 10.3233/JAD-161264</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Baker E, Iqbal E, Johnston C, Broadbent M, Shetty H, Stewart R, Howard R, Newhouse S, Khondoker M, Dobson RJB. Trajectories of dementia-related cognitive decline in a large mental health records derived patient cohort. PLoS One. 2017;12(6):0178562. DOI: 10.1371/journal.pone.0178562</mixed-citation><mixed-citation xml:lang="en">Baker E, Iqbal E, Johnston C, Broadbent M, Shetty H, Stewart R, Howard R, Newhouse S, Khondoker M, Dobson RJB. Trajectories of dementia-related cognitive decline in a large mental health records derived patient cohort. PLoS One. 2017;12(6):0178562. DOI: 10.1371/journal.pone.0178562</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Hager D, Kirk A, Morgan DG, Karunanayake C, O’Connell ME. Predictors of Cognitive Decline in a Rural and Remote Saskatchewan Population With Alzheimer’s Disease. Am. J. Alzheimers Dis. Other Demen. 2016;31(8):643–649. DOI: 10.1177/1533317516662334</mixed-citation><mixed-citation xml:lang="en">Hager D, Kirk A, Morgan DG, Karunanayake C, O’Connell ME. Predictors of Cognitive Decline in a Rural and Remote Saskatchewan Population With Alzheimer’s Disease. Am. J. Alzheimers Dis. Other Demen. 2016;31(8):643–649. DOI: 10.1177/1533317516662334</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Eldholm RS Barca ML, Persson K, Knapskog AB, Kersten H, Engedal K, Selbæk G, Brækhus A, Skovlund E, Saltvedt I. Progression of Alzheimer’s Disease: A Longitudinal Study in Norwegian Memory Clinics. J. Alzheimers Dis. 2018;61(3):1221–1232. DOI: 10.3233/JAD-170436</mixed-citation><mixed-citation xml:lang="en">Eldholm RS Barca ML, Persson K, Knapskog AB, Kersten H, Engedal K, Selbæk G, Brækhus A, Skovlund E, Saltvedt I. Progression of Alzheimer’s Disease: A Longitudinal Study in Norwegian Memory Clinics. J. Alzheimers Dis. 2018;61(3):1221–1232. DOI: 10.3233/JAD-170436</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Scheltens NME, Tijms BM, Heymans MW, Rabinovici GD, Cohn-Sheehy BI, Miller BL, Kramer JH, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Scheltens P, van der Flier WM1; Amsterdam Dementia Cohort, Alzheimer’s Disease Neuroimaging Initiative, German Dementia Competence Network, University of San Francisco Memory and Aging Center. Prominent Non-Memory Deficits in Alzheimer’s Disease Are Associated with Faster Disease Progression. J. Alzheimers Dis. 2018;65(3):1029–1039. DOI: 10.3233/JAD-171088</mixed-citation><mixed-citation xml:lang="en">Scheltens NME, Tijms BM, Heymans MW, Rabinovici GD, Cohn-Sheehy BI, Miller BL, Kramer JH, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Scheltens P, van der Flier WM1; Amsterdam Dementia Cohort, Alzheimer’s Disease Neuroimaging Initiative, German Dementia Competence Network, University of San Francisco Memory and Aging Center. Prominent Non-Memory Deficits in Alzheimer’s Disease Are Associated with Faster Disease Progression. J. Alzheimers Dis. 2018;65(3):1029–1039. DOI: 10.3233/JAD-171088</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Reisberg B, Ferris SH, Franssen EH, Shulman E, Monteiro I, Sclan SG, Steinberg G, Kluger A, Torossian C, de Leon MJ, Laska E. Mortality and Temporal Course of Probable Alzheimer’s Disease: A 5-year Prospective Study. Int. Psychogeriatrics. 1996;8(2):291–311. DOI: 10.1017/s1041610296002657</mixed-citation><mixed-citation xml:lang="en">Reisberg B, Ferris SH, Franssen EH, Shulman E, Monteiro I, Sclan SG, Steinberg G, Kluger A, Torossian C, de Leon MJ, Laska E. Mortality and Temporal Course of Probable Alzheimer’s Disease: A 5-year Prospective Study. Int. Psychogeriatrics. 1996;8(2):291–311. DOI: 10.1017/s1041610296002657</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Bowler JV, Eliasziw M, Steenhuis R, Munoz DG, Fry R, Merskey H, Hachinski VC. Comparative evolution of Alzheimer disease, vascular dementia, and mixed dementia. Arch. Neurol. 1997;54(6):697–703. DOI: 10.1001/archneur.1997.00550180021007</mixed-citation><mixed-citation xml:lang="en">Bowler JV, Eliasziw M, Steenhuis R, Munoz DG, Fry R, Merskey H, Hachinski VC. Comparative evolution of Alzheimer disease, vascular dementia, and mixed dementia. Arch. Neurol. 1997;54(6):697–703. DOI: 10.1001/archneur.1997.00550180021007</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kitabayashi Y, Ueda H, Narumoto J, Nakamura K, Kita H, Fukui K. Qualitative analysis of clock drawings in Alzheimer’s disease and vascular dementia. Psychiatry Clin. Neurosci. 2001;55(5):485–491. DOI: 10.1046/j.1440-1819.2001.00894.x</mixed-citation><mixed-citation xml:lang="en">Kitabayashi Y, Ueda H, Narumoto J, Nakamura K, Kita H, Fukui K. Qualitative analysis of clock drawings in Alzheimer’s disease and vascular dementia. Psychiatry Clin. Neurosci. 2001;55(5):485–491. DOI: 10.1046/j.1440-1819.2001.00894.x</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Villareal DT, Grant E, Miller JP, Storandt M, McKeeel DW, Morris JC Clinical outcomes of possible versus probable Alzheimer’s disease. Neurology. 2003;61:661–667. DOI: 10.1212/wnl.61.5.661</mixed-citation><mixed-citation xml:lang="en">Villareal DT, Grant E, Miller JP, Storandt M, McKeeel DW, Morris JC Clinical outcomes of possible versus probable Alzheimer’s disease. Neurology. 2003;61:661–667. DOI: 10.1212/wnl.61.5.661</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Liu-Seifert H, Siemers E, Selzler K, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. for the Alzheimer’s Disease Neuroimaging Initiative Correlation between Cognition and Function across the Spectrum of Alzheimer’s Disease. J. Prev. Alzheimers Dis. 2016;3(3):138–144. DOI: 10.14283/jpad.2016.99</mixed-citation><mixed-citation xml:lang="en">Liu-Seifert H, Siemers E, Selzler K, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. for the Alzheimer’s Disease Neuroimaging Initiative Correlation between Cognition and Function across the Spectrum of Alzheimer’s Disease. J. Prev. Alzheimers Dis. 2016;3(3):138–144. DOI: 10.14283/jpad.2016.99</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Thoma MV, Maercker A, Forstmeier S. Evidence for Different Trajectories of Delay Discounting in Older Adults With Mild Cognitive Impairment and Mild Alzheimer’s Disease. J. Gerontol. B Psychol. Sci. Soc. Sci. 2017;72(6):956-965. DOI: 10.1093/geronb/gbw010</mixed-citation><mixed-citation xml:lang="en">Thoma MV, Maercker A, Forstmeier S. Evidence for Different Trajectories of Delay Discounting in Older Adults With Mild Cognitive Impairment and Mild Alzheimer’s Disease. J. Gerontol. B Psychol. Sci. Soc. Sci. 2017;72(6):956-965. DOI: 10.1093/geronb/gbw010</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Rossetti HC, Munro Cullum C, Hynan LS, Lacritz LH. The CERAD Neuropsychologic Battery Total Score and the progression of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2010;24(2):138–142. DOI: 10.1097/WAD.0b013e3181b76415</mixed-citation><mixed-citation xml:lang="en">Rossetti HC, Munro Cullum C, Hynan LS, Lacritz LH. The CERAD Neuropsychologic Battery Total Score and the progression of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2010;24(2):138–142. DOI: 10.1097/WAD.0b013e3181b76415</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Chamberlain SR, Blackwell AD, Nathan PJ, Hammond G, Robbins TW, Hodges JR, Michael A, Semple JM, Bullmore ET, Sahakian BJ. Differential cognitive deterioration in dementia: a two year longitudinal study. J. Alzheimers Dis. 2011;24(1):125–136. DOI: 10.3233/JAD-2010-100450</mixed-citation><mixed-citation xml:lang="en">Chamberlain SR, Blackwell AD, Nathan PJ, Hammond G, Robbins TW, Hodges JR, Michael A, Semple JM, Bullmore ET, Sahakian BJ. Differential cognitive deterioration in dementia: a two year longitudinal study. J. Alzheimers Dis. 2011;24(1):125–136. DOI: 10.3233/JAD-2010-100450</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Koskas P, Henry-Feugeas MC, Feugeas JP, Ou P, Drunat O. Factors of Rapid Cognitive Decline in Late Onset Alzheimer’s Disease. Curr. Aging. Sci. 2017;10(2):129–135. DOI: 10.2174/1874609810666170102143257</mixed-citation><mixed-citation xml:lang="en">Koskas P, Henry-Feugeas MC, Feugeas JP, Ou P, Drunat O. Factors of Rapid Cognitive Decline in Late Onset Alzheimer’s Disease. Curr. Aging. Sci. 2017;10(2):129–135. DOI: 10.2174/1874609810666170102143257</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Reijs BLR, Ramakers IHGB, Köhler S, Teunissen CE, Koel-Simmelink M, Nathan PJ, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Vandenberghe R, Johannsen P, Blackwell A, Vanderstichele H, Verhey F, Visser PJ. Memory Correlates of Alzheimer’s Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. J. Alzheimers Dis. 2017;60(3):1119– 1128. DOI: 10.3233/JAD-160766</mixed-citation><mixed-citation xml:lang="en">Reijs BLR, Ramakers IHGB, Köhler S, Teunissen CE, Koel-Simmelink M, Nathan PJ, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Vandenberghe R, Johannsen P, Blackwell A, Vanderstichele H, Verhey F, Visser PJ. Memory Correlates of Alzheimer’s Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. J. Alzheimers Dis. 2017;60(3):1119– 1128. DOI: 10.3233/JAD-160766</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Tchakoute CT, Sainani KL, Henderson VW, for the Raloxifene in Alzheimer’s Disease Investigators Semantic Memory in the Clinical Progression of Alzheimer Disease. Cognitive and Behavioral Neurology. 2017;30(3):81–89. DOI: 10.1097/WNN.0000000000000131</mixed-citation><mixed-citation xml:lang="en">Tchakoute CT, Sainani KL, Henderson VW, for the Raloxifene in Alzheimer’s Disease Investigators Semantic Memory in the Clinical Progression of Alzheimer Disease. Cognitive and Behavioral Neurology. 2017;30(3):81–89. DOI: 10.1097/WNN.0000000000000131</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Mainland BJ, Herrmann N, Mallya S, Fiocco AJ, Sin G-L, Shulman KI, Ornstein TJ. Cognitive Fluctuations and Cognitive Test Performance Among Institutionalized Persons With Dementia. Am. J. Alzheimers Dis. Other. Demen. 2017;32(7):393–400. DOI: 10.1177/1533317517718954</mixed-citation><mixed-citation xml:lang="en">Mainland BJ, Herrmann N, Mallya S, Fiocco AJ, Sin G-L, Shulman KI, Ornstein TJ. Cognitive Fluctuations and Cognitive Test Performance Among Institutionalized Persons With Dementia. Am. J. Alzheimers Dis. Other. Demen. 2017;32(7):393–400. DOI: 10.1177/1533317517718954</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer’s disease. Am. J. Psychiatry. 1996;153(11):1438–43. DOI: 10.1176/ajp.153.11.1438</mixed-citation><mixed-citation xml:lang="en">Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer’s disease. Am. J. Psychiatry. 1996;153(11):1438–43. DOI: 10.1176/ajp.153.11.1438</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Tanaka H, Hashimoto M, Fukuhara R, Ishikawa T, Yatabe Y, Kaneda K, Yuuki S, Honda K, Matsuzaki S, Tsuyuguchi A, Hatada Y, Ikeda M. Relationship between dementia severity and behavioural and psychological symptoms in early-onset Alzheimer’s disease. Psychogeriatrics. 2015;15(4):242–247. DOI: 10.1111/psyg.12108</mixed-citation><mixed-citation xml:lang="en">Tanaka H, Hashimoto M, Fukuhara R, Ishikawa T, Yatabe Y, Kaneda K, Yuuki S, Honda K, Matsuzaki S, Tsuyuguchi A, Hatada Y, Ikeda M. Relationship between dementia severity and behavioural and psychological symptoms in early-onset Alzheimer’s disease. Psychogeriatrics. 2015;15(4):242–247. DOI: 10.1111/psyg.12108</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, Lyketsos CG. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study. Am. J. Psychiatry. 2015;172(5):460–465. DOI: 10.1176/appi. ajp.2014.14040480</mixed-citation><mixed-citation xml:lang="en">Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, Lyketsos CG. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study. Am. J. Psychiatry. 2015;172(5):460–465. DOI: 10.1176/appi. ajp.2014.14040480</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Paulsen JS1, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter CR, Thomas R, Grant I, Jeste DV. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54(10):1965–71. DOI: 10.1212/wnl.54.10.1965</mixed-citation><mixed-citation xml:lang="en">Paulsen JS1, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter CR, Thomas R, Grant I, Jeste DV. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54(10):1965–71. DOI: 10.1212/wnl.54.10.1965</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Seltman HJ, Mitchell S, Sweet RA. A Bayesian model of psychosis symptom trajectory in Alzheimer’s disease. Int. J. Geriatr. Psychiatry. 2016;31(2):204–210. DOI: 10.1002/gps.4326</mixed-citation><mixed-citation xml:lang="en">Seltman HJ, Mitchell S, Sweet RA. A Bayesian model of psychosis symptom trajectory in Alzheimer’s disease. Int. J. Geriatr. Psychiatry. 2016;31(2):204–210. DOI: 10.1002/gps.4326</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Barca ML, Persson K, Eldholm R, Benth JŠ, Kersten H, Knapskog AB, Saltvedt I, Selbaek G, Engedal K. Trajectories of depressive symptoms and their relationship to the progression of dementia. J. Affect. Disord. 2017;222:146–152. DOI: 10.1016/j.jad.2017.07.008</mixed-citation><mixed-citation xml:lang="en">Barca ML, Persson K, Eldholm R, Benth JŠ, Kersten H, Knapskog AB, Saltvedt I, Selbaek G, Engedal K. Trajectories of depressive symptoms and their relationship to the progression of dementia. J. Affect. Disord. 2017;222:146–152. DOI: 10.1016/j.jad.2017.07.008</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Сиденкова АП, Соколова ИВ. Влияние дефицита когнитивных функций на формирование психотических симптомов при деменциях. Фундаментальные исследования. 2014;7(4):781–785.</mixed-citation><mixed-citation xml:lang="en">Sidenkova AP, Sokolova IV. Vliyanie deficita kognitivny` x funkcij na formirovanie psixoticheskix simptomov pri demenciyax. Fundamental`ny`e issledovaniya. 2014;7(4):781–785. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Соколова ИВ, Лейдерман МВ, Сиденкова АП. Деменции с бредом. Фабулоспецефичность когнитивных функций. Уральский медицинский журнал. 2015;08(131):22–25.</mixed-citation><mixed-citation xml:lang="en">Sokolova IV, Lejderman MV, Sidenkova AP. Demencii s bredom. Fabulospecefichnost` kognitivny`x funkcij.Ural`skij medicinskij zhurnal. 2015;08(131):22–25. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Соколова ИВ, Сиденкова АП, Семке АВ. Комплексная диагностика и терапия деменций с бредом. Сибирский вестник психиатрии и наркологии. 2016;90(1):54–59.</mixed-citation><mixed-citation xml:lang="en">Sokolova IV, Sidenkova AP, Semke AV. Kompleksnaja diagnostika i terapija demencij s bredom. Sibirskij vestnik psihiatrii i narkologii. 2016;90(1):54–59. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Колыхалов ИВ. Поведенческие и психопатологические симптомы при болезни Альцгеймера: эпидемиологические, психопатологические и нейробиологические аспекты. Психиатрия. 2015;(3):74–84.</mixed-citation><mixed-citation xml:lang="en">Kolykhalov IV. Behavioral and psychopathological symptoms in Alzheimer’s disease: epidemiological, psychopathological, and neurobiological aspects. Psychiatry (Moscow). 2015;(3):74–84. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Hallikainen I, Hongisto K, Välimäki T, Hänninen T, Martikainen J, Koivisto AM. The Progression of Neuropsychiatric Symptoms in Alzheimer’s Disease During a Five-Year Follow-Up: Kuopio ALSOVA Study. J. Alzheimers Dis. 2018;61(4):1367–1376. DOI: 10.3233/JAD-170697</mixed-citation><mixed-citation xml:lang="en">Hallikainen I, Hongisto K, Välimäki T, Hänninen T, Martikainen J, Koivisto AM. The Progression of Neuropsychiatric Symptoms in Alzheimer’s Disease During a Five-Year Follow-Up: Kuopio ALSOVA Study. J. Alzheimers Dis. 2018;61(4):1367–1376. DOI: 10.3233/JAD-170697</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Lai L, Lee PE, Chan P, Fok MC, Hsiung GR, Sepehry AA. Prevalence of delusions in drug-naïve Alzheimer disease patients: A meta-analysis. Int. J. Geriatr. Psychiatry. 2019;34(9):1287–1293. DOI: 10.1002/gps.4812</mixed-citation><mixed-citation xml:lang="en">Lai L, Lee PE, Chan P, Fok MC, Hsiung GR, Sepehry AA. Prevalence of delusions in drug-naïve Alzheimer disease patients: A meta-analysis. Int. J. Geriatr. Psychiatry. 2019;34(9):1287–1293. DOI: 10.1002/gps.4812</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Ranasinghe KG, Rankin KP, Lobach IV, Kramer JH, Sturm VE, Bettcher BM, Possin K, Christine You S, Lamarre AK, Shany-Ur T, Stephens ML, Perry DC, Lee SE, Miller ZA, Gorno-Tempini ML, Rosen HJ, Boxer A, Seeley WW, Rabinovici GD1, Vossel KA, Miller BL. Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology. 2016;86(7):600–610. DOI: 10.1212/WNL.0000000000002373</mixed-citation><mixed-citation xml:lang="en">Ranasinghe KG, Rankin KP, Lobach IV, Kramer JH, Sturm VE, Bettcher BM, Possin K, Christine You S, Lamarre AK, Shany-Ur T, Stephens ML, Perry DC, Lee SE, Miller ZA, Gorno-Tempini ML, Rosen HJ, Boxer A, Seeley WW, Rabinovici GD1, Vossel KA, Miller BL. Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology. 2016;86(7):600–610. DOI: 10.1212/WNL.0000000000002373</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">van der Linde RM, Dening T, Stephan BC, Prina AM, Evans E, Brayne C. Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br. J. Psychiatry. 2016;209(5):366–377.</mixed-citation><mixed-citation xml:lang="en">van der Linde RM, Dening T, Stephan BC, Prina AM, Evans E, Brayne C. Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br. J. Psychiatry. 2016;209(5):366–377.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Haaksma ML, Leoutsakos JS, Bremer JAE, Aalten P, Ramakers IHGB, Verhey FRJ, Olde Rikkert MGM, Melis RJF. The clinical course and interrelations of dementia related symptoms. Int. Psychogeriatr. 2018;30(6):859–866. DOI: 10.1017/S1041610217000321</mixed-citation><mixed-citation xml:lang="en">Haaksma ML, Leoutsakos JS, Bremer JAE, Aalten P, Ramakers IHGB, Verhey FRJ, Olde Rikkert MGM, Melis RJF. The clinical course and interrelations of dementia related symptoms. Int. Psychogeriatr. 2018;30(6):859–866. DOI: 10.1017/S1041610217000321</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Modrego PJ, Lobo A. Determinants of Progression and Mortality in Alzheimer’s disease: A Systematic Review. Neuropsychiatry (London). 2018;8</mixed-citation><mixed-citation xml:lang="en">Modrego PJ, Lobo A. Determinants of Progression and Mortality in Alzheimer’s disease: A Systematic Review. Neuropsychiatry (London). 2018;8</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Tosto G, Monsell SE, Hawes SE, Bruno G, Mayeux R. Progression of Extrapyramidal Signs in Alzheimer’s Disease: Clinical and Neuropathological Correlates. J. Alzheimers Dis. 2016;49(4):1085–93. DOI: 10.3233/JAD-150244</mixed-citation><mixed-citation xml:lang="en">Tosto G, Monsell SE, Hawes SE, Bruno G, Mayeux R. Progression of Extrapyramidal Signs in Alzheimer’s Disease: Clinical and Neuropathological Correlates. J. Alzheimers Dis. 2016;49(4):1085–93. DOI: 10.3233/JAD-150244</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrari C, Lombardi G, Polito C, Lucidi G, Bagnoli S, Piaceri I, Nacmias B, Berti V, Rizzuto D, Fratiglioni L, Sorbi S. Alzheimer’s Disease Progression: Factors Influencing Cognitive Decline. J. Alzheimers Dis. 2018;61(2):785–791. DOI: 10.3233/JAD-170665</mixed-citation><mixed-citation xml:lang="en">Ferrari C, Lombardi G, Polito C, Lucidi G, Bagnoli S, Piaceri I, Nacmias B, Berti V, Rizzuto D, Fratiglioni L, Sorbi S. Alzheimer’s Disease Progression: Factors Influencing Cognitive Decline. J. Alzheimers Dis. 2018;61(2):785–791. DOI: 10.3233/JAD-170665</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Cadena Sanabria M, Ardila Baez M, Rueda Prada L. Status epilepticus and rapidly progressive dementia in an elderly woman. Sporadic Creutzfeldt–Jakob disease. Rev. Esp. Geriatr. Gerontol. 2015;50(2):103–104. DOI: 10.1016/j.regg.2014.10.009</mixed-citation><mixed-citation xml:lang="en">Cadena Sanabria M, Ardila Baez M, Rueda Prada L. Status epilepticus and rapidly progressive dementia in an elderly woman. Sporadic Creutzfeldt–Jakob disease. Rev. Esp. Geriatr. Gerontol. 2015;50(2):103–104. DOI: 10.1016/j.regg.2014.10.009</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Horváth A, Szűcs A, Barcs G, Noebels JL, Kamondi A. Epileptic Seizures in Alzheimer Disease: A Review. Alzheimer Dis. Assoc. Disord. 2016;30(2):186–92. DOI: 10.1097/WAD.0000000000000134</mixed-citation><mixed-citation xml:lang="en">Horváth A, Szűcs A, Barcs G, Noebels JL, Kamondi A. Epileptic Seizures in Alzheimer Disease: A Review. Alzheimer Dis. Assoc. Disord. 2016;30(2):186–92. DOI: 10.1097/WAD.0000000000000134</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">De la Torre JC. Cerebral hemodynamics and vascular risk factors: setting the stage for Alzheimer’s disease. J. Alzheimers Dis. 2012;32(3):553–567. DOI: 10.3233/JAD-2012–120793</mixed-citation><mixed-citation xml:lang="en">De la Torre JC. Cerebral hemodynamics and vascular risk factors: setting the stage for Alzheimer’s disease. J. Alzheimers Dis. 2012;32(3):553–567. DOI: 10.3233/JAD-2012–120793</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Qiao J, Lu WH, Wang J, Guo XJ, Qu QM. Vascular Risk Factors Aggravate the Progression of Alzheimer’s Disease. A 3-Year Follow-Up Study of Chinese Population. Am. J. Alzheimers Dis. Other Demen. 2014;29(6):521–5. DOI: 10.1177/1533317514522853</mixed-citation><mixed-citation xml:lang="en">Qiao J, Lu WH, Wang J, Guo XJ, Qu QM. Vascular Risk Factors Aggravate the Progression of Alzheimer’s Disease. A 3-Year Follow-Up Study of Chinese Population. Am. J. Alzheimers Dis. Other Demen. 2014;29(6):521–5. DOI: 10.1177/1533317514522853</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Richard F, Pasquier F. Can the treatment of vascular risk factors slow cognitive decline in Alzheimer’s disease patients? J. Alzheimers Dis. 2012;32(3):765–772. DOI: 10.3233/JAD-2012-121012</mixed-citation><mixed-citation xml:lang="en">Richard F, Pasquier F. Can the treatment of vascular risk factors slow cognitive decline in Alzheimer’s disease patients? J. Alzheimers Dis. 2012;32(3):765–772. DOI: 10.3233/JAD-2012-121012</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Purandare N, Burns A, Morris J, Perry EP, Wren J, McCollum C. Association of cerebral emboli with accelerated cognitive deterioration in Alzheimer’s disease and vascular dementia. Am. J. Psychiatry. 2012;169(3):300–308. DOI: 10.1176/appi.ajp.2011.11010009</mixed-citation><mixed-citation xml:lang="en">Purandare N, Burns A, Morris J, Perry EP, Wren J, McCollum C. Association of cerebral emboli with accelerated cognitive deterioration in Alzheimer’s disease and vascular dementia. Am. J. Psychiatry. 2012;169(3):300–308. DOI: 10.1176/appi.ajp.2011.11010009</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Doraiswamy PM. Silent cerebrovascular events and Alzheimer’s disease: an overlooked opportunity for prevention? Am. J. Psychiatry. 2012;169(3):251–254. DOI: 10.1176/appi.ajp.2011.11121830</mixed-citation><mixed-citation xml:lang="en">Doraiswamy PM. Silent cerebrovascular events and Alzheimer’s disease: an overlooked opportunity for prevention? Am. J. Psychiatry. 2012;169(3):251–254. DOI: 10.1176/appi.ajp.2011.11121830</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Viticchi G, Falsetti L, Buratti L, Boria C, Luzzi S, Bartolini M, Provinciali L, Silvestrini M. Framingham risk score can predict cognitive decline progression in Alzheimer’s disease. Neurobiol. Aging.2015;36(11):2940–2945. DOI: 10.1016/j.neurobiolaging.2015.07.023</mixed-citation><mixed-citation xml:lang="en">Viticchi G, Falsetti L, Buratti L, Boria C, Luzzi S, Bartolini M, Provinciali L, Silvestrini M. Framingham risk score can predict cognitive decline progression in Alzheimer’s disease. Neurobiol. Aging.2015;36(11):2940–2945. DOI: 10.1016/j.neurobiolaging.2015.07.023</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Xiang J. Carotid atherosclerosis promotes the progression of Alzheimer’s disease: A three-year prospective study. Exp. Ther. Med. 2017;14(2):1321–1326. DOI: 10.3892/etm.2017.4661</mixed-citation><mixed-citation xml:lang="en">Xiang J. Carotid atherosclerosis promotes the progression of Alzheimer’s disease: A three-year prospective study. Exp. Ther. Med. 2017;14(2):1321–1326. DOI: 10.3892/etm.2017.4661</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Bergland AK, Dalen I, Larsen AI, Aarsland D, Soennesyn H. Effect of Vascular Risk Factors on the Progression of Mild Alzheimer’s Disease and Lewy Body Dementia. J. Alzheimers Dis. 2017;56(2):575–584. DOI: 10.3233/JAD-160847</mixed-citation><mixed-citation xml:lang="en">Bergland AK, Dalen I, Larsen AI, Aarsland D, Soennesyn H. Effect of Vascular Risk Factors on the Progression of Mild Alzheimer’s Disease and Lewy Body Dementia. J. Alzheimers Dis. 2017;56(2):575–584. DOI: 10.3233/JAD-160847</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Chou PS, Kao YH, Wu MN, Chou MC, Chen CH, Lin RT, Yang YH. Effect of the Interaction Between Hypertension and Cerebral White Matter Changes on the Progression of Alzheimer Disease. Curr. Alzheimer Res. 2018;15(14):1354–1360. DOI: 10.2174/1567205015666181002141013</mixed-citation><mixed-citation xml:lang="en">Chou PS, Kao YH, Wu MN, Chou MC, Chen CH, Lin RT, Yang YH. Effect of the Interaction Between Hypertension and Cerebral White Matter Changes on the Progression of Alzheimer Disease. Curr. Alzheimer Res. 2018;15(14):1354–1360. DOI: 10.2174/1567205015666181002141013</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">de Heus RAA, Olde Rikkert MGM, Tully PJ, Lawlor BA, Claassen JAHR; NILVAD Study Group. Blood Pressure Variability and Progression of Clinical Alzheimer Disease. Hypertension. 2019;74(5):1172–1180. DOI: 10.1161/HYPERTENSIONAHA.119.13664</mixed-citation><mixed-citation xml:lang="en">de Heus RAA, Olde Rikkert MGM, Tully PJ, Lawlor BA, Claassen JAHR; NILVAD Study Group. Blood Pressure Variability and Progression of Clinical Alzheimer Disease. Hypertension. 2019;74(5):1172–1180. DOI: 10.1161/HYPERTENSIONAHA.119.13664</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Aubert L, Pichierri S, Hommet C, Camus V, Berrut G, de Decker L. Association between comorbidity burden and rapid cognitive decline in individuals with mild to moderate Alzheimer’s disease. J. Am. Geriatr. Soc. 2015;63(3):543–7. DOI: 10.1111/jgs.13314</mixed-citation><mixed-citation xml:lang="en">Aubert L, Pichierri S, Hommet C, Camus V, Berrut G, de Decker L. Association between comorbidity burden and rapid cognitive decline in individuals with mild to moderate Alzheimer’s disease. J. Am. Geriatr. Soc. 2015;63(3):543–7. DOI: 10.1111/jgs.13314</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Vita MG, Tiple D, Bizzarro A, Ladogana A, Colaizzo E, Capellari S, Rossi M, Parchi P, Masullo C, Pocchiari M. Patient with rapidly evolving neurological disease with neuropathological lesions of Creutzfeldt-Jakob disease, Lewy body dementia, chronic subcortical vascular encephalopathy and meningothelial meningioma. Neuropathology. 2017;37(2):110–115.DOI: 10.1111/neup.12343</mixed-citation><mixed-citation xml:lang="en">Vita MG, Tiple D, Bizzarro A, Ladogana A, Colaizzo E, Capellari S, Rossi M, Parchi P, Masullo C, Pocchiari M. Patient with rapidly evolving neurological disease with neuropathological lesions of Creutzfeldt-Jakob disease, Lewy body dementia, chronic subcortical vascular encephalopathy and meningothelial meningioma. Neuropathology. 2017;37(2):110–115.DOI: 10.1111/neup.12343</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Heymann D, Stern Y, Cosentino S, Tatarina-Nulman O, Dorrejo JN, Gu Y. The Association Between Alcohol Use and the Progression of Alzheimer’s Disease. Curr. Alzheimer Res. 2016;13(12):1356–1362. DOI: 10.2174/1567205013666160603005035</mixed-citation><mixed-citation xml:lang="en">Heymann D, Stern Y, Cosentino S, Tatarina-Nulman O, Dorrejo JN, Gu Y. The Association Between Alcohol Use and the Progression of Alzheimer’s Disease. Curr. Alzheimer Res. 2016;13(12):1356–1362. DOI: 10.2174/1567205013666160603005035</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Coin A, Bolzetta F, De Rui M, Veronese N, Granziera S, Girardi A, Manzato E, Sergi G. Nutritional and Global Indexes of Progression in Dementia A 12-Month Prospective Study. Am. J. Alzheimers Dis. Other Demen. 2012;27(7):504–508. DOI: 10.1177/1533317512456451</mixed-citation><mixed-citation xml:lang="en">Coin A, Bolzetta F, De Rui M, Veronese N, Granziera S, Girardi A, Manzato E, Sergi G. Nutritional and Global Indexes of Progression in Dementia A 12-Month Prospective Study. Am. J. Alzheimers Dis. Other Demen. 2012;27(7):504–508. DOI: 10.1177/1533317512456451</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Sanders CL, Wengreen HJ, Schwartz S, Behrens SJ, Corcoran C, Lyketsos CG, Tschanz JT; Cache County Investigators. Nutritional Status is Associated With Severe Dementia and Mortality: The Cache County Dementia Progression Study. Alzheimer Dis. Assoc. Disord. 2018;32(4):298–304. DOI: 10.1097/WAD.0000000000000274</mixed-citation><mixed-citation xml:lang="en">Sanders CL, Wengreen HJ, Schwartz S, Behrens SJ, Corcoran C, Lyketsos CG, Tschanz JT; Cache County Investigators. Nutritional Status is Associated With Severe Dementia and Mortality: The Cache County Dementia Progression Study. Alzheimer Dis. Assoc. Disord. 2018;32(4):298–304. DOI: 10.1097/WAD.0000000000000274</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Nelson L, Tabet N. Slowing the progression of Alzheimer’s disease; what works? Ageing. Res. Rev. 2015;23(Pt.B):193–209. DOI: 10.1016/j.arr.2015.07.002</mixed-citation><mixed-citation xml:lang="en">Nelson L, Tabet N. Slowing the progression of Alzheimer’s disease; what works? Ageing. Res. Rev. 2015;23(Pt.B):193–209. DOI: 10.1016/j.arr.2015.07.002</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">The Lancet. Dementia burden coming into focus. Lancet. 2017;390(10113):2606. DOI: 10.1016/S0140-6736(17)33304-4</mixed-citation><mixed-citation xml:lang="en">The Lancet. Dementia burden coming into focus. Lancet. 2017;390(10113):2606. DOI: 10.1016/S0140-6736(17)33304-4</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Bullock R. Drug treatment for early Alzheimers disease. Advances in Psychiatric Treatment. 1998;4:126–134. DOI: 10.1192/apt.4.3.126</mixed-citation><mixed-citation xml:lang="en">Bullock R. Drug treatment for early Alzheimers disease. Advances in Psychiatric Treatment. 1998;4:126–134. DOI: 10.1192/apt.4.3.126</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Ashford JW, Schmitt FA. Modeling the Time-course of Alzheimer Dementia. Current Psychiatry Reports. 2001;3(1):20–28. DOI: 10.1007/s11920-001-0067-1</mixed-citation><mixed-citation xml:lang="en">Ashford JW, Schmitt FA. Modeling the Time-course of Alzheimer Dementia. Current Psychiatry Reports. 2001;3(1):20–28. DOI: 10.1007/s11920-001-0067-1</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Cummings J, Fox N. Defining Disease Modifying Therapy for Alzheimer’s Disease. J. Prev. Alzheimers Dis. 2017;4(2):109–115. DOI: 10.14283/jpad.2017.12</mixed-citation><mixed-citation xml:lang="en">Cummings J, Fox N. Defining Disease Modifying Therapy for Alzheimer’s Disease. J. Prev. Alzheimers Dis. 2017;4(2):109–115. DOI: 10.14283/jpad.2017.12</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Petersen RC. Barriers for Prevention and Prodromal AD Trials. J. Prev. Alzheimers Dis. 2016;3(2):66–67. DOI: 10.14283/jpad.2016.96</mixed-citation><mixed-citation xml:lang="en">Petersen RC. Barriers for Prevention and Prodromal AD Trials. J. Prev. Alzheimers Dis. 2016;3(2):66–67. DOI: 10.14283/jpad.2016.96</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Ruthirakuhan M, Herrmann N, Suridjan I, Abraham EH, Farber I, Lanctôt KL. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease. Expert Opin. Pharmacother. 2016;17(18):2417–2429. DOI: 10.1080/14656566.2016.1258060</mixed-citation><mixed-citation xml:lang="en">Ruthirakuhan M, Herrmann N, Suridjan I, Abraham EH, Farber I, Lanctôt KL. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease. Expert Opin. Pharmacother. 2016;17(18):2417–2429. DOI: 10.1080/14656566.2016.1258060</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Grossberg GT, Tong G, Burke AD, Tariot PN. Present Algorithms and Future Treatments for Alzheimer’s Disease. J. Alzheimers Dis. 2019;67(4):1157–1171. DOI: 10.3233/JAD-180903</mixed-citation><mixed-citation xml:lang="en">Grossberg GT, Tong G, Burke AD, Tariot PN. Present Algorithms and Future Treatments for Alzheimer’s Disease. J. Alzheimers Dis. 2019;67(4):1157–1171. DOI: 10.3233/JAD-180903</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Aisen PS, Raman R. Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business. J. Prev. Alz. Dis. 2020; Published online March 6, 2020, DOI: 10.14283/jpad.2020.20</mixed-citation><mixed-citation xml:lang="en">Aisen PS, Raman R. Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business. J. Prev. Alz. Dis. 2020; Published online March 6, 2020, DOI: 10.14283/jpad.2020.20</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry. 2002;72:310–314. DOI: 10.1136/jnnp.72.3.310</mixed-citation><mixed-citation xml:lang="en">Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry. 2002;72:310–314. DOI: 10.1136/jnnp.72.3.310</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Doody R, Dunn J, Clark C, Farlow M, Foster N, Liao T, Gonzales N, Lai E, Massman P. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2001;12:295–300. DOI: 10.1159/000051272</mixed-citation><mixed-citation xml:lang="en">Doody R, Dunn J, Clark C, Farlow M, Foster N, Liao T, Gonzales N, Lai E, Massman P. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2001;12:295–300. DOI: 10.1159/000051272</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Doody R. We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer’s disease drug development. Alzheimers Dement. 2008;4:21–25. DOI: 10.1016/j.jalz.2007.10.010</mixed-citation><mixed-citation xml:lang="en">Doody R. We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer’s disease drug development. Alzheimers Dement. 2008;4:21–25. DOI: 10.1016/j.jalz.2007.10.010</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res. Ther. 2009;1(2):7–11. DOI: 10.1186/alzrt7</mixed-citation><mixed-citation xml:lang="en">Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res. Ther. 2009;1(2):7–11. DOI: 10.1186/alzrt7</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Rountree S. Factors that influence survival in Alzheimer’s patients. Alzheimer’s &amp; Dementia: The Journal of the Alzheimer’s Association. 2011;7(4):513.</mixed-citation><mixed-citation xml:lang="en">Rountree S. Factors that influence survival in Alzheimer’s patients. Alzheimer’s &amp; Dementia: The Journal of the Alzheimer’s Association. 2011;7(4):513.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement. 2013;9(3):338–345. DOI: 10.1016/j.jalz.2012.01.002</mixed-citation><mixed-citation xml:lang="en">Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement. 2013;9(3):338–345. DOI: 10.1016/j.jalz.2012.01.002</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2008;2(3):209–221. DOI: 10.1097/WAD.0b013e31816653bc</mixed-citation><mixed-citation xml:lang="en">Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2008;2(3):209–221. DOI: 10.1097/WAD.0b013e31816653bc</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Wattmo C, Wallin ÅK, Londos E, Minthon L. Longterm outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis. Assoc. Disord. 2011;25(1):63–72. DOI: 10.1097/WAD.0b013e3181f5dd97</mixed-citation><mixed-citation xml:lang="en">Wattmo C, Wallin ÅK, Londos E, Minthon L. Longterm outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis. Assoc. Disord. 2011;25(1):63–72. DOI: 10.1097/WAD.0b013e3181f5dd97</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Wattmo C, Londos E, Minthon L. Longitudinal Associations between Survival in Alzheimer’s Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services. Dement. Geriatr. Cogn. Disord. 2015;40(5–6):297–310. DOI: 10.1159/000437050</mixed-citation><mixed-citation xml:lang="en">Wattmo C, Londos E, Minthon L. Longitudinal Associations between Survival in Alzheimer’s Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services. Dement. Geriatr. Cogn. Disord. 2015;40(5–6):297–310. DOI: 10.1159/000437050</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Wattmo C, Minthon L, Wallin ÅK. Mild versus moderate stages of Alzheimer’s disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. Alzheimers Res. Ther. 2016;8:7–12. DOI: 10.1186/s13195-016-0174-1</mixed-citation><mixed-citation xml:lang="en">Wattmo C, Minthon L, Wallin ÅK. Mild versus moderate stages of Alzheimer’s disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. Alzheimers Res. Ther. 2016;8:7–12. DOI: 10.1186/s13195-016-0174-1</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Wattmo C, Wallin ÅK. Early — versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years. Alzheimer’s Res. Ther. 2017;9(1):70–74. DOI: 10.1186/s13195-017-0294-2</mixed-citation><mixed-citation xml:lang="en">Wattmo C, Wallin ÅK. Early — versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years. Alzheimer’s Res. Ther. 2017;9(1):70–74. DOI: 10.1186/s13195-017-0294-2</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Droogsma E, van Asselt D, van Steijn J, Diekhuis M, Veeger N, De Deyn PP. Long-term Course of Alzheimer Disease in Patients Treated According to the Dutch Dementia Guideline at a Memory Clinic: A “Real-Life” Study. Alzheimer Dis. Assoc. Disord. 2016;30(1):53–59. DOI: 10.1097/WAD.0000000000000090</mixed-citation><mixed-citation xml:lang="en">Droogsma E, van Asselt D, van Steijn J, Diekhuis M, Veeger N, De Deyn PP. Long-term Course of Alzheimer Disease in Patients Treated According to the Dutch Dementia Guideline at a Memory Clinic: A “Real-Life” Study. Alzheimer Dis. Assoc. Disord. 2016;30(1):53–59. DOI: 10.1097/WAD.0000000000000090</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Castagna A, Cotroneo AM, Ruotolo G, Gareri P. The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia. Study Clin. Drug Investig. 2016;36(12):1059–1065. DOI: 10.1007/s40261-016-0454-3</mixed-citation><mixed-citation xml:lang="en">Castagna A, Cotroneo AM, Ruotolo G, Gareri P. The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia. Study Clin. Drug Investig. 2016;36(12):1059–1065. DOI: 10.1007/s40261-016-0454-3</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Xu SX, Samtani MN, Russu A, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Brashear HR, Styren S, Hu C. Alzheimer’s disease progression model using disability assessment for dementia scores from bapineuzumab trials. Alzheimers Dement (N Y). 2015;1(2):141–149. DOI: 10.1016/j.trci.2015.06.005</mixed-citation><mixed-citation xml:lang="en">Xu SX, Samtani MN, Russu A, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Brashear HR, Styren S, Hu C. Alzheimer’s disease progression model using disability assessment for dementia scores from bapineuzumab trials. Alzheimers Dement (N Y). 2015;1(2):141–149. DOI: 10.1016/j.trci.2015.06.005</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Choe YM, Kim KW, Jhoo JH, Ryu SH, Seo EH, Sohn BK, Byun MS, Bak JH, Lee JM, Yun HJ, Han MI, Woo JI, Lee DY. Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer’s disease. Int. J. Geriatr. Psychiatry. 2016;31(7):731–739. DOI: 10.1002/gps.4384</mixed-citation><mixed-citation xml:lang="en">Choe YM, Kim KW, Jhoo JH, Ryu SH, Seo EH, Sohn BK, Byun MS, Bak JH, Lee JM, Yun HJ, Han MI, Woo JI, Lee DY. Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer’s disease. Int. J. Geriatr. Psychiatry. 2016;31(7):731–739. DOI: 10.1002/gps.4384</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Pavlik VN, Doody RS, Rountree SD, Darby E. Vitamin E Use Is Associated with Improved Survival in an Alzheimer’s Disease Cohort. Dement. Geriatr. Cogn. Disord. 2009;28(6):536–540. DOI: 10.1159/000255105</mixed-citation><mixed-citation xml:lang="en">Pavlik VN, Doody RS, Rountree SD, Darby E. Vitamin E Use Is Associated with Improved Survival in an Alzheimer’s Disease Cohort. Dement. Geriatr. Cogn. Disord. 2009;28(6):536–540. DOI: 10.1159/000255105</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset PJ, Vellas B; REAL.FR study group. Long-term progression of Alzheimer’s disease in patients under antidementia drugs. Alzheimers Dement. 2011;7(6):579–592. DOI: 10.1016/j.jalz.2011.02.009</mixed-citation><mixed-citation xml:lang="en">Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset PJ, Vellas B; REAL.FR study group. Long-term progression of Alzheimer’s disease in patients under antidementia drugs. Alzheimers Dement. 2011;7(6):579–592. DOI: 10.1016/j.jalz.2011.02.009</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Hu K, Riemersma-van der Lek RF, Patxot M, Li P, Shea SA, Scheer FA, Van Someren EJ. Progression of Dementia Assessed by Temporal Correlations of Physical Activity: Results From a 3.5-Year, Longitudinal Randomized Controlled Trial. Sci. Rep. 2016;6:27742. DOI: 10.1038/srep27742</mixed-citation><mixed-citation xml:lang="en">Hu K, Riemersma-van der Lek RF, Patxot M, Li P, Shea SA, Scheer FA, Van Someren EJ. Progression of Dementia Assessed by Temporal Correlations of Physical Activity: Results From a 3.5-Year, Longitudinal Randomized Controlled Trial. Sci. Rep. 2016;6:27742. DOI: 10.1038/srep27742</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Koivisto AM, Hallikainen I, Välimäki T, Hongisto K, Hiltunen A, Karppi P, Sivenius J, Soininen H, Martikainen J. Early psychosocial intervention does not delay institutionalization in persons with mild Alzheimer disease and has impact on neither disease progression nor caregivers’ well-being: ALSO VA 3-year follow-up. Int. J. Geriatr. Psychiatry.2016;31(3):273–283. DOI: 10.1002/gps.4321</mixed-citation><mixed-citation xml:lang="en">Koivisto AM, Hallikainen I, Välimäki T, Hongisto K, Hiltunen A, Karppi P, Sivenius J, Soininen H, Martikainen J. Early psychosocial intervention does not delay institutionalization in persons with mild Alzheimer disease and has impact on neither disease progression nor caregivers’ well-being: ALSO VA 3-year follow-up. Int. J. Geriatr. Psychiatry.2016;31(3):273–283. DOI: 10.1002/gps.4321</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Duan Y, Lu L, Chen J, Wu C, Liang J, Zheng Y, Wu J, Rong P, Tang C. Psychosocial interventions for Alzheimer’s disease cognitive symptoms: a Bayesian network meta-analysis. BMC Geriatr. 2018;18(1):175. Published 2018 Aug 7. DOI: 10.1186/s12877-018-0864-6</mixed-citation><mixed-citation xml:lang="en">Duan Y, Lu L, Chen J, Wu C, Liang J, Zheng Y, Wu J, Rong P, Tang C. Psychosocial interventions for Alzheimer’s disease cognitive symptoms: a Bayesian network meta-analysis. BMC Geriatr. 2018;18(1):175. Published 2018 Aug 7. DOI: 10.1186/s12877-018-0864-6</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Khan I, Petrou S, Khan K, Mistry D, Lall R, Sheehan B, Lamb S; DAPA Trial Group. Does Structured Exercise Improve Cognitive Impairment in People with Mild to Moderate Dementia? A Cost-Effectiveness Analysis from a Confirmatory Randomised Controlled Trial: The Dementia and Physical Activity (DAPA) Trial. Pharmacoecon Open. 2018 Sep 11. DOI: 10.1007/s41669-018-0097-9</mixed-citation><mixed-citation xml:lang="en">Khan I, Petrou S, Khan K, Mistry D, Lall R, Sheehan B, Lamb S; DAPA Trial Group. Does Structured Exercise Improve Cognitive Impairment in People with Mild to Moderate Dementia? A Cost-Effectiveness Analysis from a Confirmatory Randomised Controlled Trial: The Dementia and Physical Activity (DAPA) Trial. Pharmacoecon Open. 2018 Sep 11. DOI: 10.1007/s41669-018-0097-9</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Minn YK, Choi SH, Suh YJ, Jeong JH, Kim EJ, Kim JH, Park KW, Park MH, Youn YC, Yoon B, Choi SJ, Oh YK, Yoon SJ. Effect of Physical Activity on the Progression of Alzheimer’s Disease: The Clinical Research Center for Dementia of South Korea Study. J. Alzheimers Dis. 2018;66(1):249–261. DOI: 10.3233/JAD-180333</mixed-citation><mixed-citation xml:lang="en">Minn YK, Choi SH, Suh YJ, Jeong JH, Kim EJ, Kim JH, Park KW, Park MH, Youn YC, Yoon B, Choi SJ, Oh YK, Yoon SJ. Effect of Physical Activity on the Progression of Alzheimer’s Disease: The Clinical Research Center for Dementia of South Korea Study. J. Alzheimers Dis. 2018;66(1):249–261. DOI: 10.3233/JAD-180333</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Borges-Machado F, Ribeiro Ó, Sampaio A. Feasibility and Impact of a Multicomponent Exercise Intervention in Patients With Alzheimer’s Disease: A Pilot Study. Am. J. Alzheimers Dis. Other Demen. 2019;34(2):95–103. Research Article DOI: 10.1177/1533317518813555</mixed-citation><mixed-citation xml:lang="en">Borges-Machado F, Ribeiro Ó, Sampaio A. Feasibility and Impact of a Multicomponent Exercise Intervention in Patients With Alzheimer’s Disease: A Pilot Study. Am. J. Alzheimers Dis. Other Demen. 2019;34(2):95–103. Research Article DOI: 10.1177/1533317518813555</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Noble W, Spires-Jones TL. Sleep well to slow Alzheimer’s progression? Science. 2019;363(6429):813–814. DOI: 10.1126/science.aaw5583</mixed-citation><mixed-citation xml:lang="en">Noble W, Spires-Jones TL. Sleep well to slow Alzheimer’s progression? Science. 2019;363(6429):813–814. DOI: 10.1126/science.aaw5583</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Webster L, Groskreutz D, Grinbergs–Saull A, Howard R, O’Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, Roberts C, McCleery J, Pickett J, Bunn F, Challis D, Charlesworth G, Featherstone K, Fox C, Goodman C, Jones R, Lamb S, Moniz- Cook E, Schneider J, Shepperd S, Surr C, Thompson-Coon J, Ballard C, Brayne C, Burke O, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Murtagh F, Robinson L, Livingston G. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technol. Assess. 2017;21(26):1–192. DOI: 10.3310/hta21260</mixed-citation><mixed-citation xml:lang="en">Webster L, Groskreutz D, Grinbergs–Saull A, Howard R, O’Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, Roberts C, McCleery J, Pickett J, Bunn F, Challis D, Charlesworth G, Featherstone K, Fox C, Goodman C, Jones R, Lamb S, Moniz- Cook E, Schneider J, Shepperd S, Surr C, Thompson-Coon J, Ballard C, Brayne C, Burke O, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Murtagh F, Robinson L, Livingston G. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technol. Assess. 2017;21(26):1–192. DOI: 10.3310/hta21260</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Bazzari FH, Abdallah DM, El-Abhar HS. Pharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far. Curr. Alzheimer Res. 2019;16(3):261–277. DOI: 10.2174/1567205016666190301111120</mixed-citation><mixed-citation xml:lang="en">Bazzari FH, Abdallah DM, El-Abhar HS. Pharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far. Curr. Alzheimer Res. 2019;16(3):261–277. DOI: 10.2174/1567205016666190301111120</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, Roberts C, McCleery J, Pickett J, Bunn F, Challis D, Charlesworth G, Featherstone K, Fox C, Goodman C, Jones R, Lamb S, Moniz-Cook E, Schneider J, Shepperd S, Surr C, Thompson-Coon J, Ballard C, Brayne C, Burke O, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Murtagh F, Robinson L, Livingston G. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technol. Assess. 2017;21(26):1–192. DOI: 10.3310/hta21260</mixed-citation><mixed-citation xml:lang="en">Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, Banerjee S, Woods B, Perneczky R, Lafortune L, Roberts C, McCleery J, Pickett J, Bunn F, Challis D, Charlesworth G, Featherstone K, Fox C, Goodman C, Jones R, Lamb S, Moniz-Cook E, Schneider J, Shepperd S, Surr C, Thompson-Coon J, Ballard C, Brayne C, Burke O, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Murtagh F, Robinson L, Livingston G. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technol. Assess. 2017;21(26):1–192. DOI: 10.3310/hta21260</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Borges-Machado F, Ribeiro Ó, Sampaio A. Feasibility and Impact of a Multicomponent Exercise Intervention in Patients With Alzheimer’s Disease: A Pilot Study. Am. J. Alzheimers Dis. Other Demen. 2019;34(2):95–103. Research Article DOI: 10.1177/1533317518813555</mixed-citation><mixed-citation xml:lang="en">Borges-Machado F, Ribeiro Ó, Sampaio A. Feasibility and Impact of a Multicomponent Exercise Intervention in Patients With Alzheimer’s Disease: A Pilot Study. Am. J. Alzheimers Dis. Other Demen. 2019;34(2):95–103. Research Article DOI: 10.1177/1533317518813555</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Gauthier S, Aisen PS, Cummings J, Detke MJ, Longo FM, Raman R, Sabbagh M, Schneider L, Tanzi R, Tariot P, Weiner M, Touchon J, Vellas B and the EU/US CTAD Task Force. Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force. J. Prev. Alz. Dis. 2020. Published online April 6,2020 DOI: 10.14283/jpad.2020.18</mixed-citation><mixed-citation xml:lang="en">Gauthier S, Aisen PS, Cummings J, Detke MJ, Longo FM, Raman R, Sabbagh M, Schneider L, Tanzi R, Tariot P, Weiner M, Touchon J, Vellas B and the EU/US CTAD Task Force. Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force. J. Prev. Alz. Dis. 2020. Published online April 6,2020 DOI: 10.14283/jpad.2020.18</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
